Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tara Biosystems

Explore full profile

Tara Biosystems Revolutionizing “human-on-a-chip technology by providing PREDICTIVE CARDIAC PHYSIOLOGY

New York City, United StatesFounded 2014Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2020
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Tara Biosystems and the history behind them.

About Tara Biosystems

TARA Biosystems operates in the biotechnology sector, specializing in predictive cardiac models to enhance drug discovery and development for heart diseases. The company leverages a groundbreaking stem cell tissue engineering platform to create reproducible, functioning human heart tissue in the lab. This technology is trusted by over 30 pharmaceutical and biotechnology companies to predict clinical responses of new medicines for heart failure and other cardiac conditions. TARA's core clients include pharmaceutical companies, biotech firms, and research institutions focused on cardiac drug discovery and safety. The business model revolves around providing tailored solutions for each partner, ensuring that every project meets specific needs and objectives. TARA generates revenue through partnerships, research collaborations, and service contracts. The company operates in the global biotechnology market, focusing on precision cardiology and cardiac safety.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2014
Headquarters
New York City, United States
Open positions
None listed
Dealroom signal
56.1/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Predictive Analytics, Biotechnology, Drug Development, Cardiology and cardiovascular, Spinout, Tech for Biotech and Pharma, organ-on-chip, DT and LS
Technology
Big Data, Deep Tech
Client focus
b2b
Links
WebsiteX

Latest news

Press, funding announcements and product moves mentioning Tara Biosystems.

See all news

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Apr 2022 $0 — Valo Health ↗
SERIES AEquity / VC Nov 2021 $0 — Undisclosed —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Tara Biosystems website traffic

Latest recorded traffic for Tara Biosystems is 650 monthly website visits, down 24.4% over the last three months.

Latest monthly visits650 3-month web change-24.4%
Monthly website visitsOct 2017–Oct 2022
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
BiomimXDeveloping beating organs-on-chip platforms as in vitro pre-clinical models to improve the drug development process Milan, Italy Operational 13 $2.5M $1.1M
AllelicaSoftware as a Service that allows clinical genetics lab to perform Polygenic Risk Score analysis New York City, United States Operational
Pear TherapeuticsPear discovers, develops, and commercializes Prescription Digital Therapeutics to treat diseases with high unmet need Boston, United States Operational
ARTIC TechnologiesDevelops microscale fluid control solutions inspired by nature for advanced cell culture platforms Eindhoven, Netherlands Operational
Quris TechnologiesAn artificial intelligence innovator that is disrupting the drug development process Tel Aviv-Yafo, Israel Operational
CyclicaDiscovering Drug through Proteome Docking to advance molecules that embrace the complexity of the disease Toronto, Canada Acquired
twoXARImproving Health Through Computation Palo Alto, United States Operational
NeuroKaireGenetika+ is developing a tailored medical diagnostic instrument to help doctors cure depression. Genetika+ predicts the best pharmacological treatment for each patient, allowing faster treatment Kearny, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • 180 Degree Capital

Series A9 investors entered at this stage

  • Morgan Noble
  • OMX Ventures
  • Alexandria Venture Investments
  • Tachyon Valley BioLabs
  • DEFTA Partners
  • Partnership Fund for New York City
  • Mérieux Equity Partners
  • Lifeforce Capital
  • Trancos Ventures

Other known investors6 additional known investors

  • Columbia University
  • University of Toronto
  • Valo Health
  • Harlem Biospace
  • Korys
  • New York Ventures

Talent

Book a demo to see the people
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tara Biosystems on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tara Biosystems’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.